Biogen Shares Resume Trading, Rise 2.5% Following Thursday's FDA Approval of Alzheimer's Drug Leqembi
Portfolio Pulse from Charles Gross
Biogen's shares resumed trading and rose 2.5% following the FDA's approval of its Alzheimer's drug, Leqembi, on Thursday.
July 07, 2023 | 11:16 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Biogen's stock rose 2.5% following the FDA's approval of its Alzheimer's drug, Leqembi.
The FDA's approval of Biogen's Alzheimer's drug, Leqembi, is a significant positive development for the company. This approval could potentially lead to increased sales and revenues for Biogen, which is reflected in the 2.5% rise in the company's stock.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100